

South Carolina Department of Health and Human Services

(SCDHHS) Pharmacy and Therapeutics Committee

Microsoft Teams Attendee Registration Link:

<https://events.gcc.teams.microsoft.com/event/55fe9daf-b090-4d85-bbe0-5b2c5422b85b@45843448-87c2-4911-a7e2-1079f0f4aac3>

Wednesday, May 7, 2025, 4:00pm

A G E N D A

I. Welcome..... Edward Behling, MD

*Freedom of Information Act/Americans With Disabilities Act Compliance Pledge – This body's official minutes will indicate that this meeting is in compliance with the Freedom of Information Act's mandate that the public be notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.*

II. Roll Call ..... Kim Bristow, RPh

III. Approval of Minutes from February 5, 2025 ..... P&T Committee

IV. State Updates ..... Kevin Wessinger, MD and Kim Bristow, RPh

V. New Drugs to Market.....Lisa Correll, PharmD

VI. Public Comment - Drug Classes

a. Presenters must pre-register with SCDHHS no less than seven days in advance of the meeting. Testimony will be limited to three minutes, and there will be only one speaker per pharmaceutical agent under consideration. P&T Committee members may use an additional two minutes to ask the speaker questions, if warranted. Please e-mail the speaker's name, the product they will discuss, and the CV of the speaker. Additionally, a completed speaker disclosure statement must be faxed to our P&T Pharmacist at 888-656-1239. The form can be found at: <http://southcarolina.fhsc.com/providers/ptcommittee.asp>. SCDHHS will need all this information no later than the close of business May 1, 2025. Emails may be sent to [scsinglepdl@primetherapeutics.com](mailto:scsinglepdl@primetherapeutics.com) or via fax to (888) 656- 1239.

b. Criteria for Re-Reviews: Previously reviewed therapeutic classes from PDL phases subject to re-review may be opened for re-review if one or more of the following has occurred: a) a new drug in the therapeutic class, b) a new indication for an existing drug in the therapeutic class, c) a new study recognized and generally accepted by the medical community or three peer-reviewed studies for a drug in the therapeutic class.

VII. Drug Classes for P&T Committee Review ..... P&T Committee

**Classes for Re-review:**

Immunomodulators, Atopic Dermatitis Topical

Steroids, Medium Potency

Neuropathic Pain

Corticosteroids, Inhaler Devices

Antimigraine Treatments, CGRP Modulators

ACE Inhibitors and Combinations

Beta Adrenergic Devices, Short Acting Inhalers

VIII. Brand to Generic Switches..... Blake Cook, RPh

IX. House Keeping..... Blake Cook, RPh

a. Next P&T Meeting – Wednesday August 6, 2025

X. Adjournment